Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

References

• PearseAGThe cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the conceptJ Histochem Cytochem19691753033134143745
   PubMed Web of Science ®Google Scholar
• MoertelCGKarnofsky memorial lecture. An odyssey in the land of small tumorsJ Clin Oncol1987510150215222443618
   PubMedGoogle Scholar
• YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• HalfdanarsonTRRabeKGRubinJPetersenGMPancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnn Oncol200819101727173318515795
   PubMed Web of Science ®Google Scholar
• BerardiRRinaldiSTorniaiMGastrointestinal neuroendocrine tumors: searching the optimal treatment strategy. A literature reviewCrit Rev Oncol Hematol20169826427426643525
   PubMed Web of Science ®Google Scholar
• RinkeAMüllerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMĆwikłaJBLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMĆwikłaJBAnti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension studyEndocr Relat Cancer201623319119926743120
   PubMed Web of Science ®Google Scholar
• RinkeAWittenbergMSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survivalNeuroendocrinology20171041263226731483
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, IncNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Neuroendocrine Tumors Version 1.2015112014
   Google Scholar
• NCCN Guidelines^® & Clinical Resources. NCCN Drugs & Biologics Compendium^® Available from: https://www.nccn.org/professionals/drug_compendium/content/contents.aspAccessed April 24, 2015
   Google Scholar
• Financial Burden of Cancer Care|Cancer Trends Progress Report Available from: http://progressreport.cancer.gov/after/economic_burden#field_most_recent_estimatesAccessed May 3, 2016
   Google Scholar
• EpsteinAMJhaAKOravEJAnalysis of early accountable care organizations defines patient, structural, cost, and quality-of-care characteristicsHealth Aff (Millwood)20143319510224395940
   PubMed Web of Science ®Google Scholar
• PeppercornJThe financial burden of cancer care: do patients in the US know what to expect?Expert Rev Pharmacoecon Outcomes Res201414683584225269513
   PubMed Web of Science ®Google Scholar
• MauskopfJASullivanSDAnnemansLPrinciples of good practice for budget impact analysis: report of the ISPOR task force on good research practices budget impact analysisValue Health200710533634717888098
   PubMed Web of Science ®Google Scholar
• SullivanSDMauskopfJAAugustovskiFBudget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task forceValue Health201417151424438712
   PubMed Web of Science ®Google Scholar
• ModlinIMObergKChungDCGastroenteropancreatic neuroendocrine tumoursLancet Oncol200891617218177818
   PubMed Web of Science ®Google Scholar
• FeroneDForsytheABakkerBPedersiniRGorenAReal world data on patients with neuroendocrine tumors treated with octreotide LARPoster presented at: European Cancer Congress 2013 (ESMO)September 27 – October 1 2013Amsterdam, Netherlands
   Google Scholar
• HalletJLawCHCukierMSaskinRLiuNSinghSExploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomesCancer2015121458959725312765
   PubMed Web of Science ®Google Scholar
• PokuriVKFongMKIyerROctreotide and lanreotide in gastroenteropancreatic neuroendocrine tumorsCurr Oncol Rep2016181726743514
   PubMed Web of Science ®Google Scholar
• StrosbergJCascianoRSternLUnited States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatmentWorld J Gastroenterol201319152348235423613628
   PubMed Web of Science ®Google Scholar
• Wolters KluwerPrice Rx Available from: https://pricerx.medispan.com/. Published 2016Accessed April 25, 2017
   Google Scholar
• Novartis Pharmaceuticals CorporationSandostatin LAR [Prescribing Information]122014 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdfAccessed April 20, 2017
   Google Scholar
• SOMATULINE^® DEPOT (lanreotide) injection [prescribing Information]Ipsen Biopharmaceuticals, Inc2014
   Google Scholar
• StrosbergJRBensonABHuynhLClinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review studyThe Oncologist201419993093625096997
   PubMed Web of Science ®Google Scholar
• XuYShihYTLearyCShenCYaoJCDosing patterns of octreotide LAR among elderly patients with neuroendocrine tumors: Analysis of the SEER-Medicare databaseJ Clin Oncol201230Supple14550
   Google Scholar
• ShenCXuYYaoJCShihYTOctreotide LAR use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysisJ Clin Oncol201230Suppl 432222184371
   PubMed Web of Science ®Google Scholar
• KulkeMHHorschDCaplinM37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)Eur J Cancer201551Suppl 3S728
   Web of Science ®Google Scholar
• FisherMaxine DPulgarSoniaTreatment patterns and outcomes in metastatic neuroendocrine tumors: results from a retrospective community oncology databasePresented at: North American Neuroendocrine Tumor Society Symposium15–17 October, 2015Austin, TX, USA
   Google Scholar
• StrosbergJonathan RBobiakSarahZornosaCarrie CDosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes databaseJ Clin Oncol201331Suppl 154142
   Web of Science ®Google Scholar
• U.S. Bureau of Labor StatisticsOccupation Employment Statistics Available from: http://www.bls.gov/oes/current/oes291171.htm. Published March 2016Accessed March 28, 2016
   Google Scholar
• AdelmanDTBurgessADaviesPREvaluation of long-acting somatostatin analog injection devices by nurses: a quantitative studyMed Devices (Auckl)2012510310923293542
   PubMedGoogle Scholar
• BoydAEDeFordLLMaresJEImproving the success rate of gluteal intramuscular injectionsPancreas201342587888223508015
   PubMed Web of Science ®Google Scholar
• ZaybakAGüneşÜYTamselSKhorshidLEserIDoes obesity prevent the needle from reaching muscle in intramuscular injections?J Adv Nurs200758655255617484745
   PubMed Web of Science ®Google Scholar
• CockshottWPThompsonGTHowlettLJSeeleyETIntramuscular or intralipomatous injections?N Engl J Med198230763563587088101
   PubMed Web of Science ®Google Scholar
• NisbetACIntramuscular gluteal injections in the increasingly obese population: retrospective studyBMJ2006332754263763816524934
   PubMed Web of Science ®Google Scholar
• ChanVOColvilleJPersaudTBuckleyOHamiltonSTorreggianiWCIntramuscular injections into the buttocks: are they truly intramuscular?Eur J Radiol200658348048416495027
   PubMed Web of Science ®Google Scholar
• FazioNSpadaFReal-word analysis on the use of somatostatin analogs (SSAs) in patients with neuroendocrine neoplasms (NENs): results of a survey conducted by the Italian Society of Medical Oncology (AIOM)Ann Oncol201627suppl 4iv114
   Web of Science ®Google Scholar
• ModicaRRamundoVMarcielloFHigh-dose treatment with somatostatin analogues in neuroendocrine tumoursEndocr Abstr201537EP1132
   Google Scholar
• RuszniewskiPValleJWLombard-BohasCPatient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: an international observational studyDig Liver Dis201648555255826917486
   PubMedGoogle Scholar
• Van FraeyenhoveFMeiresonNTerriereLHigh-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case reportCase Rep Oncol20147115516324707264
   PubMedGoogle Scholar
• StrosbergJEl-HaddadGWolinEPhase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumorsN Engl J Med201737612513528076709
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporate Fact Sheet12016 Available from: https://www.novartis.com/sites/www.novartis.com/files/2a_Pharmaceuticals_EN.pdfAccessed May 4, 2016
   Google Scholar
• AyyagariRajeevNearyMaureenLiShangEconomic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumorsPresented at: North American Neuroendocrine Tumor Society Symposium10–11 October, 2014Nashville, TN, USA
   Google Scholar
• VinikAaronWolin EdwardMHeleneAduryGomez-Panzani EddaLELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs) [abstract]J Clin Oncol2014 Available from: http://meetinglibrary.asco.org/content/123139-143Accessed July 22, 2016
   Google Scholar